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Regulatory CD19+CD24hiCD38hi B cells are decreased in patients with 
coronary atherosclerosis and have impaired interleukin-10 production in 
response to CpG 
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Aim: B-lymphocytes have critical roles in the inflammatory process that drives 
atherosclerosis. In animal models, conventional B2 B cells promote 
atherosclerosis, whilst innate B1a B cells are protective. B cells with 
regulatory function (Bregs) have been identified in animals and humans and 
have been implicated in the pathogenesis of autoimmunity. Whether Bregs 
have a role in human atherosclerosis is currently unknown. Our aim was to 
characterise the frequency, phenotype and function of Bregs in 
atherosclerosis patients. 
Methods: CD19+CD24hiCD38hi Bregs were quantified in patients with 
atherosclerosis (myocardial infarction, MI, n=60; stable angina, SA, n=40), 
and in healthy subjects (n=30) using flow cytometry. Interleukin-10 (IL-10) 
production was quantified by intracellular staining. 
Results: The percentage and absolute number of circulating Bregs were 
markedly reduced in MI and SA patients compared to healthy subjects. No 
differences were noted in total, mature or memory B cells, suggesting a 
specific depletion of the Breg cell subset. Bregs from MI and SA patients 
produced significantly less IL-10 in response to CpG but not CD40L compared 
to Bregs from healthy subjects. IL-10 production by mature and memory B 
cells was not impaired. Molecular mechanisms that underlie defects in Bregs 
in patients with atherosclerosis are being characterised. 
Conclusions: Our data show for the first time that patients with 
atherosclerosis harbour marked numerical and functional defects in Breg cells 
that may tip the balance in favour of pro-inflammatory B and T lymphocytes. A 
better understanding of these defects may reveal novel targets for therapies 
to tackle inflammation in atherosclerosis. 
